v3.24.0.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Operating expenses:        
Research and development $ 48,338 $ 42,252 $ 146,872 $ 108,420
Acquired in-process research and development 0 10,000 12,500 10,000
General and administrative 13,215 11,775 42,458 35,597
Total operating expenses 61,553 64,027 201,830 154,017
Interest income (8,933) (2,944) (16,569) (4,098)
Other (income) expense, net (1,094) 1,757 (1,579) 609
Loss before provision (benefit) for income taxes (51,526) (62,840) (183,682) (150,528)
Provision (benefit) for income taxes (108) 387 335 1,000
Net loss $ (51,418) $ (63,227) $ (184,017) $ (151,528)
Net loss per common share - basic (in dollars per share) $ (0.36) $ (0.49) $ (1.36) $ (1.26)
Net loss per common share - diluted (in dollars per share) $ (0.36) $ (0.49) $ (1.36) $ (1.26)
Weighted-average common shares outstanding – basic (in shares) 144,523,034 128,574,190 135,577,267 120,665,299
Weighted-average common shares outstanding – diluted (in shares) 144,523,034 128,574,190 135,577,267 120,665,299

Source